# Reinforcement Learning: Strengths for Oncology Clinical Trials with Physical AI

## Overview

Reinforcement learning (RL) is uniquely suited to oncology applications where decisions
unfold sequentially over time and interact with physical systems. Unlike supervised learning,
which maps inputs to static labels, RL optimizes cumulative long-term outcomes — exactly the
objective in treatment planning, robotic surgery, and adaptive radiation therapy. In federated
settings, RL enables multi-site policy learning without centralizing sensitive patient
trajectories.

## 1. Adaptive Treatment Planning

Cancer treatment is inherently sequential: chemotherapy cycles, radiation fractions,
immunotherapy schedules, and surgical timing all depend on evolving patient state.

- **Dynamic Treatment Regimes (DTRs)**: RL formalizes cancer treatment as a Markov Decision
  Process where states encode patient condition (tumor size, biomarkers, toxicity levels),
  actions represent treatment decisions (drug selection, dosing, schedule), and rewards
  capture long-term outcomes (survival, quality of life). This formulation naturally handles
  the credit assignment problem — attributing outcomes to earlier decisions.
- **Batch RL from observational data**: Algorithms like Fitted Q-Iteration (FQI), Conservative
  Q-Learning (CQL), and Decision Transformer can learn treatment policies from retrospective
  clinical data without requiring online interaction with patients. This is critical because
  exploratory treatment decisions on real patients are ethically impermissible.
- **Personalized treatment sequences**: RL policies adapt to individual patient trajectories,
  recommending different treatment intensification or de-escalation based on observed response.
  This goes beyond the static risk stratification that supervised classifiers provide.
- **Reference**: Tseng et al., "Deep Reinforcement Learning for Personalized Treatment
  Recommendation," AAAI 2017; Gottesman et al., "Guidelines for Reinforcement Learning in
  Healthcare," Nature Medicine, 2019.

## 2. Robotic Surgical Control

Physical AI systems performing autonomous or semi-autonomous surgical tasks represent the
most direct application of RL in oncology.

- **Continuous control with safety constraints**: RL algorithms (SAC, PPO, TD3) trained in
  simulation can learn smooth, precise control policies for robotic arms performing tumor
  resection, biopsy needle insertion, or catheter navigation. Constrained RL formulations
  (e.g., CPO, RCPO) encode hard safety boundaries such as maximum force, keep-out zones
  around critical anatomy, and instrument velocity limits.
- **Sim-to-real transfer for surgical robotics**: High-fidelity surgical simulators (e.g.,
  those built on NVIDIA Isaac Sim, SOFA, or Ambf) enable training millions of episodes before
  deploying on physical platforms. Domain randomization of tissue properties, lighting, and
  camera angles produces robust policies that transfer to real surgical environments.
- **Learned dexterity**: RL can discover manipulation strategies that handcrafted controllers
  cannot — for example, learning optimal trocar angles for minimally invasive surgery or
  adaptive suturing policies that respond to tissue deformation in real time.
- **Reference**: Scheikl et al., "LapGym — An Open Source Framework for Reinforcement
  Learning in Robot-Assisted Laparoscopic Surgery," ICRA 2023.

## 3. Radiation Dose Optimization

Radiation therapy planning requires balancing tumor dose coverage against toxicity to
surrounding organs — a sequential optimization problem that RL handles naturally.

- **Fractionation schedule optimization**: RL agents learn personalized fractionation
  schedules that maximize tumor control probability (TCP) while maintaining organ-at-risk
  (OAR) doses below tolerance thresholds. Unlike fixed protocols, RL-derived schedules
  adapt fraction doses based on imaging-assessed tumor response between fractions.
- **Beam angle and fluence optimization**: RL formulations for intensity-modulated radiation
  therapy (IMRT) and volumetric-modulated arc therapy (VMAT) optimize beam configurations
  end-to-end, jointly considering deliverability constraints and dose objectives.
- **Adaptive replanning**: When tumor geometry changes during a multi-week treatment course
  (due to tumor shrinkage or patient weight loss), RL agents can trigger and guide replanning
  decisions faster than traditional optimization-based replanning workflows.
- **Reference**: Tseng et al., "Deep Reinforcement Learning for Automated Radiation
  Adaptation in Lung Cancer," Medical Physics, 2017; Shen et al., "Operating a treatment
  planning system using a deep-reinforcement learning-based virtual treatment planner,"
  Medical Physics, 2020.

## 4. Federated Policy Learning

RL in federated settings enables multi-institutional policy optimization without sharing
patient-level trajectory data.

- **Federated Q-function aggregation**: Sites train local Q-networks on their patient
  trajectories and share Q-function parameters (not trajectory data) with the federation.
  Aggregated Q-functions represent treatment value estimates informed by diverse patient
  populations across all participating institutions.
- **Heterogeneous treatment protocols as exploration**: Different sites following different
  treatment protocols (e.g., NCCN vs ESMO guidelines) naturally provide behavioral policy
  diversity, which is beneficial for off-policy RL. The federation effectively benefits from
  a broader behavioral policy than any single site would have.
- **Federated reward shaping**: Sites can collaboratively define and refine reward functions
  through federated governance, ensuring that RL policies optimize for endpoints agreed upon
  by the multi-institutional trial committee.
- **Privacy-preserving trajectory encoding**: Techniques like federated representation
  learning compress patient trajectories into privacy-preserving embeddings before sharing,
  enabling richer policy learning than gradient-only communication.

## 5. Exploration and Discovery of Novel Strategies

- **Beyond human heuristics**: RL agents can discover treatment combinations and sequences
  that clinicians have not considered, similar to how AlphaGo discovered novel Go strategies.
  In oncology, this might mean identifying optimal sequencing of immunotherapy and
  chemotherapy that clinical trials have not yet tested.
- **Counterfactual reasoning**: Model-based RL approaches build internal models of patient
  dynamics that enable counterfactual reasoning — "what would have happened if we had
  switched to Drug B at week 4?" This capability supports trial design and hypothesis
  generation.
- **Multi-objective optimization**: RL naturally handles multi-objective reward functions
  that balance efficacy, toxicity, cost, and quality of life — trade-offs that are difficult
  to encode in supervised learning but essential for clinical decision-making.

## 6. Integration with Physical AI Feedback Loops

- **Closed-loop control**: RL agents can process real-time feedback from Physical AI sensors
  (force sensors, imaging, vital signs) and adjust actions accordingly, enabling closed-loop
  control that supervised models cannot provide.
- **Online adaptation**: Meta-RL and contextual RL approaches allow rapid adaptation to
  new patients or new surgical contexts with minimal additional data, supporting the
  personalization requirements of precision oncology.
- **Hierarchical control**: Hierarchical RL decomposes complex surgical procedures into
  subtask policies (approach, dissection, hemostasis, closure), each optimized independently
  but coordinated by a high-level policy — mirroring how experienced surgeons organize their
  decision-making.

## Summary

Reinforcement learning's core strength — optimizing sequential decisions under uncertainty
for long-term outcomes — aligns directly with the fundamental challenges of oncology treatment
and Physical AI control. Federated RL further enables multi-institutional policy learning
from diverse treatment experiences. While significant challenges remain (see limitations
document), RL represents the most promising paradigm for adaptive, personalized oncology
care integrated with autonomous Physical AI systems.
